Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hookipa Pharma Inc (NQ: HOOK )

5.595 -0.225 (-3.87%)
Streaming Delayed Price Updated: 12:38 PM EDT, Aug 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hookipa Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Why HOOKIPA Pharma (HOOK) Stock Is Volatile Today
HOOKIPA Pharma shares are trading lower by 10.9% during Monday's session. The company announced a 1-for-10 reverse stock split. 
Via Benzinga
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Deep Dive Into HOOKIPA Pharma Stock: Analyst Perspectives (4 Ratings)
Via Benzinga
Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views
Via Benzinga
Keurig Dr Pepper To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma: Q4 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns. 
Via InvestorPlace
HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024
HOOK stock results show that HOOKIPA Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... 
Via Benzinga
Exposures Product Safety
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx. 
Via Benzinga
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023
HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.